

Carmenta Bioscience Founder Honored by White House as “Champion of Change”

Atul Butte, MD, Ph.D., Receiving Award for Open Science

PALO ALTO, Calif.-- (PRESS RELEASE) Carmenta Bioscience, Inc., a privately held medical technology company focused on maternal and fetal health, today announced Atul Butte, MD, Ph.D., Carmenta Co-Founder and Co-Chair of the Scientific Advisory Board, will receive the “Champion of Change Award” at the White House.

Dr. Butte will be recognized and honored with 12 other national leaders for their pioneering use of “open data” in biomedical research. Dr. Butte leveraged open data in his systems biology approach to the discovery and development of serum-based tests for the diagnosis and prediction of preeclampsia at Stanford University. Preeclampsia is a leading cause of preterm birth and maternal/fetal death, arising in 5-8% of pregnant mothers and characterized by high blood pressure and protein in the urine after week 20 of pregnancy.

Dr. Butte is Chief, Division of Systems Medicine in the Department of Pediatrics and an Associate Professor at Stanford University School of Medicine and Lucile Packard Children's Hospital. Dr. Butte’s lab at Stanford uses computational, open data methods that convert more than 400 trillion points of molecular, clinical, and epidemiological data into diagnostics, therapeutics, and new disease insights.

The White House Champions of Change program was created as part of President Obama’s Winning the Future initiative. Through this program, the White House highlights individuals, businesses, and organizations whose extraordinary stories and accomplishments positively impact society. To learn more about the White House Champions of Change program, visit www.whitehouse.gov/champions.

“Our work at Carmenta is an example of how open data can result in game-changing scientific discoveries and inventions that help improve the lives of mothers and newborns,” commented Dr. Butte.

Carmenta CEO, Dr. Matthew Cooper, stated, “We are very pleased to see Dr. Butte honored for his contributions and leadership in open science. We also applaud the White House for recognizing the importance of this paradigm shift in biomedical research.”

About Carmenta Bioscience

Carmenta Bioscience is a privately held, medical technology company focused on advancing maternal and fetal health by applying a systems biology approach to the diagnosis and

prediction of preeclampsia. Carmenta's products in development combine proprietary computational algorithms with novel serum protein measurements to classify pregnant mothers at risk for preeclampsia. For more information regarding Carmenta, please visit www.carmentabio.com.

Contacts

Carmenta Bioscience, Inc.
Matthew Cooper, 650-308-8544
info@carmentabio.com

To watch this event live, visit www.whitehouse.gov/live at 1:00 pm ET on June 20th. To learn more about the White House Champions of Change program, visit www.whitehouse.gov/champions.

